Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 3,489 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $29.12, for a total value of $101,599.68. Following the sale, the director owned 737,770 shares of the company’s stock, valued at approximately $21,483,862.40. The trade was a 0.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cyrus Harmon also recently made the following trade(s):

• On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total transaction of $82,194.93.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ:OLMA opened at $27.14 on Tuesday. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $36.26. The firm has a market capitalization of $1.86 billion, a P/E ratio of -14.51 and a beta of 1.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company’s fifty day moving average price is $25.45 and its 200 day moving average price is $13.55.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OLMA has been the subject of a number of research reports. Guggenheim assumed coverage on Olema Pharmaceuticals in a research note on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright upped their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. increased their price target on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. The Goldman Sachs Group raised their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, UBS Group assumed coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued a “buy” rating and a $45.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several institutional investors have recently bought and sold shares of OLMA. Ameritas Investment Partners Inc. lifted its stake in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock worth $29,000 after acquiring an additional 5,866 shares during the period. FNY Investment Advisers LLC increased its stake in shares of Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 5,000 shares during the period. Russell Investments Group Ltd. purchased a new position in Olema Pharmaceuticals during the third quarter worth about $53,000. Finally, American Century Companies Inc. acquired a new stake in Olema Pharmaceuticals in the second quarter valued at about $54,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.